FDA grants approval to manufacture Collagenase SANTYL Ointment at DPT Laboratories' facility

Healthpoint today announced that the U.S. Food and Drug Administration has granted approval to manufacture commercial supplies of Collagenase SANTYL® Ointment, a biologic enzymatic debriding agent, at DPT Laboratories' Center of Excellence for Sterile & Specialty Products facility in Lakewood, New Jersey. DPT Laboratories is one of Healthpoint's contract manufacturers for the brand.

"The approval of this second production facility marks a significant milestone for the SANTYL® brand, allowing us to immediately double our manufacturing capacity for this important therapeutic agent," said Travis E. Baugh, President and Chief Operating Officer of Healthpoint. "The approval culminates a multi-year effort undertaken to ensure continuous, uninterrupted supply to the healthcare community of the only FDA-approved enzymatic debrider available in the United States."